Multi-Target Inhibitor of ZJQ- 3 F Against AChE/BACE1/GSK3β Targets Improves the Cognitive Impairment of APP/PS1/Tau Triple-Transgenic Mouse Models of Alzheimer's Disease
- PMID: 40285940
- DOI: 10.1007/s12035-025-04982-7
Multi-Target Inhibitor of ZJQ- 3 F Against AChE/BACE1/GSK3β Targets Improves the Cognitive Impairment of APP/PS1/Tau Triple-Transgenic Mouse Models of Alzheimer's Disease
Erratum in
-
Correction: Multi-Target Inhibitor of ZJQ- 3 F Against AChE/BACE1/GSK3β Targets Improves the Cognitive Impairment of APP/PS1/Tau Triple-Transgenic Mouse Models of Alzheimer's Disease.Mol Neurobiol. 2025 Dec;62(12):16681-16683. doi: 10.1007/s12035-025-05265-x. Mol Neurobiol. 2025. PMID: 40773006 No abstract available.
Abstract
Background: Alzheimer's disease (AD) is a multifactorial neuropathology characterized by the accumulation of amyloid-beta (Aβ) plaques, neurofibrillary tangles (NFTs) and cholinergic system dysfunction. At present, there is no effective treatment strategy for AD. Our previous research showed that ZJQ-3F acts as an inhibitor of AChE/BACE1/GSK3β, and showed good blood-brain barrier permeability, appropriate bioavailability and oral safety. In order to further study, the protective effect of ZJQ-3F on APP/PS1/Tau transgenic mice was determined.
Methods: APP/PS1/Tau transgenic mice model of AD was treated with ZJQ-3F from the age of 8 to 12 months, and then behavioral tests was conducted. Western blot, immunohistochemistry and immunofluorescence staining were used to evaluate the level of tau protein, Aβ plaques and synaptic function.
Results: Our results revealed that administration of ZJQ-3F could improve the cognitive function of APP/PS1/Tau transgenic mice. In addition, compared with APP/PS1/Tau mice, the protein expression levels of tau protein phosphorylation site at Ser396, Thr212 and Thr181 in the cortex and hippocampus of ZJQ-3F treated mice was significantly decreased. Moreover, the results showed that ZJQ-3F significantly reduced the deposition of Aβ in the cortex and hippocampus. Furthermore, the results indicated that the protein expression levels of PSD95, SYP and SYT in the cortex and hippocampus were increased markedly after ZJQ-3F was given.
Conclusions: Our studies suggest that the chronic administration of ZJQ-3F can improve learning and memory ability, reduce tau protein phosphorylation, reduce Aβ deposition and improve synaptic dysfunction in APP/PS1/Tau transgenic model of AD, indicating that ZJQ-3F can be used as a multi-target inhibitor to slow down the progress of AD.
Keywords: AChE; APP/PS1/Tau; Alzheimer’s disease; BACE1; GSK3β; Multi-target.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Ethical Approval: All animal experiments were subject to approval by the Institutional Animal Care and Use Committee at Shenyang Pharmaceutical University. Consent to Participate: Not applicable. Consent for Publication: All authors agreed with the content and gave explicit consent to the formulation and publication of this work. Competing interests: The authors declare no competing interests.
References
-
- Fedele E (2023) Anti-Amyloid Therapies for Alzheimer’s Disease and the Amyloid Cascade Hypothesis. Int J Mol Sci 24. https://doi.org/10.3390/ijms241914499
-
- Alzheimer's disease facts and figures (2023) Alzheimers Dement 19:1598–1695
-
- Ettcheto M, Cano A, Busquets O et al (2019) A metabolic perspective of late onset Alzheimer’s disease. Pharmacol Res 145. https://doi.org/10.1016/j.phrs.2019.104255
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
